Subodh Verma

MD, PhD, FRCSC, FAHA

Scientist

Biography

Please note: Dr. Verma will not take students in summer.

Dr. Subodh Verma is an internationally renowned cardiac surgeon-scientist and Professor at the University of Toronto. He is the current Canada Research Chair in Cardiovascular Surgery, having previously served as the Canada Research Chair in Atherosclerosis (2007-2017). Dr. Verma was recently awarded the 2021 Lister Prize in Surgery from the University of Toronto in recognition of his outstanding and continuing productivity of international stature. He is a past recipient of the Howard Morgan Award for Distinguished Achievements in Cardiovascular Research and the Royal College of Physicians and Surgeons of Canada Gold Medal in Surgery. He is an appointee of the American Association of Thoracic Surgeons (AATS) and a member of the College of New Scholars, Artists and Scientists, Royal Society of Canada. According to Google Scholar in April 2021, Dr. Verma has an h-index of 100 and his work has been cited over 50,000 times.

Dr. Verma has published extensively in highly impactful journals like the NEJM, Lancet, Circulation, JACC, Nature, and JCI. He is an Associate Editor of the European Heart Journal. Dr. Verma is an active contributor to Canadian clinical practice guidelines and co-authored the recently updated recommendations for atrial fibrillation, antiplatelet therapy, diabetes, and heart failure; he was a member of the 2018 AATS consensus guidelines committee on bicuspid aortic valve-related aortopathy. Dr. Verma has served in various capacities on the American Heart Association Council on Cardiovascular Surgery and Anesthesia since 2008.

Dr. Verma had/has leadership roles on 10 contemporary global heart failure trials – several of which have let to paradigm changes in how individuals all around the world who live with diabetes and heart failure are now managed. He founded and oversees the CardioLink platform at St Michael’s Hospital that is conducting cardiometabolic and surgically oriented RCTs and translational studies.

Dr. Verma leads a dynamic pre-clinical and translational research team that leverages pre-clinical disease models and clinical trial-derived data to identify novel mediators of cardiovascular and cardiometabolic disease as well as answer timely and relevant healthcare questions. His research has yielded 2 United States patents and is supported by several national peer-reviewed grants.

 

Recent Publications

  1. Kosiborod, MN, Esterline, R, Furtado, RHM, Oscarsson, J, Gasparyan, SB, Koch, GG et al.. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021; :. doi: 10.1016/S2213-8587(21)00180-7. PubMed PMID:34302745 PubMed Central PMC8294807.
  2. Hess, DA, Terenzi, DC, Verma, S. Heal Thyself: SGLT2 Inhibition Limits Regenerative Cell Exhaustion and Heals Damaged Vessels. Diabetes. 2021; :. doi: 10.2337/dbi21-0025. PubMed PMID:34285122 .
  3. Oliveira, AN, Yanagawa, B, Quan, A, Verma, S, Hood, DA. Human cardiac ischemia-reperfusion injury: Blunted stress response with age. J Card Surg. 2021; :. doi: 10.1111/jocs.15807. PubMed PMID:34250631 .
  4. Bakbak, E, Terenzi, DC, Trac, JZ, Teoh, H, Quan, A, Glazer, SA et al.. Lessons from bariatric surgery: Can increased GLP-1 enhance vascular repair during cardiometabolic-based chronic disease?. Rev Endocr Metab Disord. 2021; :. doi: 10.1007/s11154-021-09669-7. PubMed PMID:34228302 .
  5. Lam, CSP, Ferreira, JP, Pfarr, E, Sim, D, Tsutsui, H, Anker, SD et al.. Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J. 2021; :. doi: 10.1093/eurheartj/ehab360. PubMed PMID:34184057 .
  6. Sharma, A, Aziz, H, Verma, S, Abramson, BL, Choi, R, Chua, GL et al.. Permission to prescribe: do cardiologists need permission to prescribe diabetes medications that afford cardiovascular benefit?. Curr Opin Cardiol. 2021; :. doi: 10.1097/HCO.0000000000000892. PubMed PMID:34173772 .
  7. Lee, JA, Yanagawa, B, An, KR, Arora, RC, Verma, S, Friedrich, JO et al.. Frailty and pre-frailty in cardiac surgery: a systematic review and meta-analysis of 66,448 patients. J Cardiothorac Surg. 2021;16 (1):184. doi: 10.1186/s13019-021-01541-8. PubMed PMID:34172059 PubMed Central PMC8229742.
  8. Szarek, M, Bhatt, DL, Steg, PG, Cannon, CP, Leiter, LA, McGuire, DK et al.. Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial. Ann Intern Med. 2021; :. doi: 10.7326/M21-0651. PubMed PMID:34152828 .
  9. Verma, S, Leiter, LA, Zinman, B, Sharma, A, Mattheus, M, Fitchett, D et al.. Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial. ESC Heart Fail. 2021;8 (4):2603-2607. doi: 10.1002/ehf2.13374. PubMed PMID:34132492 PubMed Central PMC8318423.
  10. Verma, S, Latter, DA, Bonow, RO. Failed Mitral TEER: Are There Lessons for Decision Making?. J Am Coll Cardiol. 2021;78 (1):10-13. doi: 10.1016/j.jacc.2021.04.086. PubMed PMID:34059390 .
Search PubMed

Affiliations & Other Activities

  • Cardiac Surgeon, Division of Cardiology , St. Michael’s Hospital
  • Professor of Surgery and Pharmacology & Toxicology, University of Toronto
  • Canada Research Chair in Cardiovascular Surgery
X